PROZAC by Eli Lilly and Company is unknown, it is presumed to be linked to its inhibition of cns neuronal uptake of serotonin. Approved for depressive episodes associated with bipolar i disorder, the treatment of treatment resistant depression. First approved in 1999.
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
PROZAC (fluoxetine) is an oral small-molecule antidepressant approved in 1999 for depressive episodes associated with Bipolar I Disorder and treatment-resistant depression. It works by inhibiting CNS neuronal uptake of serotonin, though its complete mechanism of action remains incompletely understood.
Product is in late-lifecycle phase with modest Part D utilization (12K claims, $22M spend), signaling potential team consolidation and shift toward legacy brand management or product discontinuation planning.
unknown, it is presumed to be linked to its inhibition of CNS neuronal uptake of serotonin.
Fasting Study of Fluoxetine Capsules 40 mg and Prozac Pulvules 40 mg
To Demonstrate the Relative Bioavailability of Geneva and Dista (Prozac) 20 mg Fluoxetine Hydrochloride Capsules (Pulvules) In Healthy Adult Males Under Fasting Conditions
To Demonstrate the Relative Bioavailability of Geneva and Dista (Prozac) 20 mg Fluoxetine Hydrochloride Capsules (Pulvules) In Healthy Adult Males Under Fed and Fasted Conditions
Worked on PROZAC at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moPROZAC offers limited career growth opportunities given its LOE-approaching lifecycle and zero linked job openings. Roles on this product typically focus on defending market share, managing generic competition, and optimizing commercial efficiency rather than driving innovation or expansion.